Amar Sawhney

Amar is the President and CEO of Octux, Inc. a company focused on unmet needs in ophthalmic surgical wound closure and drug delivery. Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company. He was Chairman of marketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence. Before Confluent, Amar was the technology founder of Focal, Inc. (acquired by Genzyme). Amar’s innovations are the subject of almost 100 issued and pending patents. He is a board member of Soteira, Square One and TiE Boston. He is a board member and founder of Access Closure, Octux, Augmenix, and Incept LLC. Amar volunteers his time with entrepreneurial organizations including TiE Boston, MassMedic, and the E&Y Entrepreneur of the Year program